SonoVue

SonoVue

Manufacturer:

Bracco

Distributor:

DCH Auriga
Concise Prescribing Info
Contents
Sulphur hexafluoride
Indications/Uses
Diagnostic agent to enhance the echogenicity of the blood or fluids in the urinary tract. Transpulmonary echocardiographic contrast agent in adult patients w/ suspected or established CV disease to provide opacification of cardiac chambers & enhances left ventricular endocardial border delineation. Increases the accuracy in detection or exclusion of abnormalities in cerebral arteries & extracranial carotid or peripheral arteries in adult patients by improving the doppler signal to noise ratio; increases the quality of doppler flow image & duration of clinically-useful signal enhancement in portal vein assessment. Improves display of the vascularity of liver & breast lesions during doppler sonography in adult patients. Ultrasonography of the excretory tract in paed patients from newborn to 18 yr to detect vesicoureteral reflux.
Dosage/Direction for Use
IV Adult B-mode imaging of cardiac chambers at rest or w/ stress 2 mL. Vascular doppler imaging 2.4 mL, a 2nd inj can be made during a single exam. Every inj should be followed by a flush w/ 5 mL of NaCl 0.9% soln for inj. Intravesical Paed patient Recommended dose: 1 mL.
Contraindications
Hypersensitivity. Right-to-left shunts, severe pulmonary HTN (pulmonary artery pressure >90 mmHg), uncontrolled systemic HTN & adult resp distress syndrome. Not to be used in combination w/ dobutamine in patients w/ conditions suggesting CV instability where dobutamine is contraindicated.
Special Precautions
Serious hypersensitivity reactions in patients w/ no prior exposure to sulphur hexafluoride microbubbles products; may increase risk of serious reactions in patients w/ prior hypersensitivity reaction to polyethylene glycol; closely supervise patients during & for at least 30 min following administration. Treating anaphylaxis w/ epinephrine in patients on β-blockers. Perform ECG monitoring in high-risk patients w/ unstable cardiopulmonary status as clinically indicated. Patients w/ recent acute coronary syndrome or clinically unstable ischaemic cardiac disease including evolving or ongoing MI, typical angina at rest w/in last 7 days, significant worsening of cardiac symptoms w/in last 7 days, recent coronary artery intervention or other factors suggesting clinical instability, acute cardiac failure, class III/IV cardiac failure or severe rhythm disorders. Patients must have a stable condition when used in conjunction w/ stress echocardiography during the 2 preceding days. Perform ECG & BP monitoring during SonoVue-enhanced echocardiography w/ pharmacological stress (eg, dobutamine). Acute endocarditis, prosthetic valves, acute systemic inflammation &/or sepsis, hyperactive coagulation states &/or recent thromboembolism, end-stage renal or hepatic disease. False -ve cases can occur w/ voiding ultrasonography w/ SonoVue. Contains Na <1 mmol. Avoid use during pregnancy. Not known if sulphur hexafluoride is excreted in human milk; may consider to resume breastfeeding 2-3 hr after administration. Safety & efficacy in patients <18 yr has not been established for IV administration & use in echocardiography & vascular doppler imaging.
Adverse Reactions
Headache, inj site reaction, nausea.
MIMS Class
Radiographic & Diagnostic Agents
ATC Classification
V08DA05 - sulfur hexafluoride, phospholipid microspheres ; Belongs to the class of ultrasound agents used as ultrasound contrast media.
Presentation/Packing
Form
SonoVue powd for inj 8 mirolitre/mL
Packing/Price
(+ 5 mL solvent pre-filled syringe) 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in